Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells 806 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 806 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the sale, the insider now owns 112,221 shares of the company’s stock, valued at approximately $5,538,106.35. The trade was a 0.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total transaction of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The stock was sold at an average price of $46.81, for a total transaction of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total transaction of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00.

Twist Bioscience Price Performance

Shares of NASDAQ TWST traded up $1.64 during midday trading on Wednesday, reaching $53.66. 942,523 shares of the stock were exchanged, compared to its average volume of 781,392. The business has a 50-day simple moving average of $48.63 and a two-hundred day simple moving average of $46.21. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -14.91 and a beta of 1.87. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The business’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.75) earnings per share. Equities research analysts expect that Twist Bioscience Co. will post -2.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience during the third quarter worth $34,000. Van ECK Associates Corp raised its holdings in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the period. Signaturefd LLC raised its holdings in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the period. US Bancorp DE raised its holdings in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares during the period. Finally, Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the third quarter worth $95,000.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TWST. Scotiabank raised their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a report on Tuesday. Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday. Wolfe Research initiated coverage on shares of Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Barclays decreased their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Finally, JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.